- |||||||||| metformin / Generic mfg.
Journal: Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties. (Pubmed Central) - Nov 5, 2017 Thus, metabolic inhibitors of glycolysis such as 2-deoxy-D-glucose (2DG) and of the mitochondrial respiratory pathway, such as metformin, were evaluated as potential therapeutic agents against a panel of EWS cell lines in vitro...Furthermore, we demonstrate that the use of metabolic modulators can target putative EWS stem cells, both in vitro and in vivo, and potentially overcome chemotherapeutic resistance in EWS. Based on these data, clinical strategies using drugs targeting tumor cell metabolism present a viable therapeutic modality against EWS.
- |||||||||| Journal: Targeting isocitrate dehydrogenase (IDH) in cancer. (Pubmed Central) - Nov 5, 2017
Preliminary results from phase I clinical trials with IDH inhibitors in patients with advanced hematologic malignancies have demonstrated an objective response rate ranging from 31% to 40% with durable responses (>1 year) observed. Furthermore, the IDH inhibitors have demonstrated early signals of activity in solid tumors with IDH mutations, including cholangiocarcinomas and low grade gliomas.
- |||||||||| Journal: Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma. (Pubmed Central) - Nov 5, 2017
Despite the near-synchronous presentation of 2 unrelated sarcomas, extensive genomic analyses did not reveal any unifying somatic or germline mutations nor any apparent cancer predisposition. This case also highlights the potential role of utilizing plasma cell-free DNA for diagnosing tumors in locations where biopsy confers high morbidity.
- |||||||||| Biomarker, Review, Journal: Autophagy as a potential target for sarcoma treatment. (Pubmed Central) - Nov 5, 2017
Additionally, some co-regulators of autophagy have also been investigated as promising biomarkers for the diagnosis and prognosis of sarcoma. In this review, we summarize contemporary advances in the role of autophagy in sarcoma and discuss the potential of autophagy as a new target for sarcoma treatment.
- |||||||||| Xalkori (crizotinib) / Pfizer
Journal: An activating KIT mutation induces crizotinib resistance in ROS1 positive lung cancer. (Pubmed Central) - Nov 3, 2017 Activation of KIT by a gain-of-function somatic mutation is a novel mechanism of resistance to crizotinib in ROS1-rearranged NSCLC. This bypass signaling pathway serves as a ROS1-independent mechanism of resistance, similarly to previously identified epidermal growth factor receptor or Kirsten rat sarcoma viral oncogene homolog/neuroblastoma RAS viral oncogene homolog signaling pathways, and can potentially be targeted by KIT inhibitors.
- |||||||||| Journal: The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated With Radiotherapy. (Pubmed Central) - Nov 3, 2017
In patients undergoing radiation therapy and limb-sparing surgery for soft tissue sarcoma, the quantitative width of the negative margin does not influence outcome, and so attempts at wide margins of resection appear to be unnecessary, especially when such attempts compromise the functional outcome. Importantly, the conclusions drawn from this study must not be applied to those patients undergoing surgery alone as the local treatment of their soft tissue sarcoma, in which case wider margins of resection may be necessary.
- |||||||||| Biomarker, Journal: Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. (Pubmed Central) - Nov 2, 2017
This is a case report of an Ewing sarcoma patient with metastatic disease recurrence <2 years after standard chemotherapy/radiation who achieved a durable and sustained complete response after 2 series of treatments with Vigil (GMCSF/bi-shRNA furin DNA autologous tumor immunotherapy) serially manufactured from first and second recurrences with ELISPOT assay correlation. Results support justification of further testing of Vigil with ELISPOT assay as a biomarker to assess level of immune response and correlation with disease control.
- |||||||||| Journal: Clinical case series of pediatric hepatic angiosarcoma. (Pubmed Central) - Nov 2, 2017
Seven were initially diagnosed with an infantile hepatic hemangioendothelioma (IHHE) or hemangioma and the eighth with a "vascular tumor." Two patients, who received liver transplant, survived. We suggest hepatic hemangiomas can rarely transform into angiosarcomas and a subset of IHHEs (Type II) are actually a low-grade form of angiosarcoma rather than a benign lesion.
- |||||||||| Journal: Unusual abdominal metastases in osteosarcoma. (Pubmed Central) - Nov 1, 2017
Awareness of and surveillance for unusual patterns of metastasis may allow for earlier detection, intervention, and palliative care decision-making, which may affect survival and quality of life. This report underlines the need for prospective studies evaluating surveillance guidelines for patients after medical and surgical management of osteosarcoma, especially in cases complicated by pulmonary metastases.
- |||||||||| sasanlimab (PF-06801591) / Pfizer
Trial primary completion date, Metastases: A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors (clinicaltrials.gov) - Oct 31, 2017 P1, N=150, Recruiting, Suspended --> Recruiting | Trial primary completion date: Jul 2018 --> Oct 2018 Trial primary completion date: Nov 2018 --> May 2019
- |||||||||| Journal: Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. (Pubmed Central) - Oct 28, 2017
Excellent local control can be achieved with a coordinated strategy of preoperative (±intraoperative) XRT combined with aggressive en bloc surgical resection of RPS, but systemic failure remains a problem for higher-grade tumors. Patients with ES are at high risk for relapse/progression and second cancers.
- |||||||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Halaven (eribulin mesylate) / Eisai
Review, Journal: Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma? (Pubmed Central) - Oct 28, 2017 Also, to be further investigated is the use of trabectedin in sarcoma subtypes which were excluded from the phase III study, but in which activity has been documented in earlier trials and subsequent reports. Combinations of trabectedin with other agents, particularly doxorubicin, have been explored, but the data to date do not support the routine use of these regimens.
- |||||||||| PX-478 / Seagen
Journal: Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma. (Pubmed Central) - Oct 28, 2017 Consistent with these findings, we observed a significant inhibition of growth of PEL in normoxia upon HIF-1α suppression achieved by either HIF-1α knockdown or treatment with PX-478, a small molecule inhibitor of HIF-1α. These results offer further evidence that HIF-1α plays a critical role in the pathogenesis of PEL, and that inhibition of HIF-1α can be a potential therapeutic strategy in this disease.
- |||||||||| Enrollment change: Genomic Structural Variation in Cancer Susceptibility (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=1850, Enrolling by invitation, Recruiting --> Active, not recruiting | N=24 --> 17 | Trial primary completion date: Jul 2019 --> Mar 2017 N=1250 --> 1850
- |||||||||| adavosertib (AZD1775) / AstraZeneca
Trial primary completion date, Combination therapy: Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Oct 24, 2017 P1/2, N=128, Recruiting, Unlike t(1;10), BRAF rearrangements were only found in MIFS but not in 6 hemosiderotic fibrolipomatous tumor (HFLT) lacking TGFBR3-MGEA5 fusions (including 2 pure HFLT, 2 hybrid HFLT-MIFS, and 2 associated with pleomorphic hyalinizing angiectatic tumors). Trial primary completion date: Oct 2017 --> Apr 2021
|